Crinetics Pharmaceuticals, Inc. — Director's Dealing 2020

Feb 12, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2020-02-07

Reporting Person: Vivo Capital VIII, LLC (10% Owner)
Reporting Person: Vivo Capital Fund VIII, L.P. (10% Owner)
Reporting Person: Vivo Capital Surplus Fund VIII, L.P. (10% Owner)
Reporting Person: Vivo Opportunity, LLC (10% Owner)
Reporting Person: Vivo Opportunity Fund, L.P. (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-07	Common Stock	S	1134	$22.0	Disposed	2723843	Indirect
2020-02-07	Common Stock	S	157	$22.0	Disposed	376128	Indirect
2020-02-07	Common Stock	S	4614	$22.0	Disposed	174202	Indirect
2020-02-10	Common Stock	S	1451	$21.4	Disposed	2722392	Indirect
2020-02-10	Common Stock	S	200	$21.4	Disposed	375928	Indirect
2020-02-10	Common Stock	S	5904	$21.4	Disposed	168298	Indirect

Footnotes

F1: These securities are held of record by Vivo Capital Fund VIII, L.P. ("VCF").

F2: These securities are held of record by Vivo Capital Surplus Fund VIII, L.P. ("VCSF").

F3: These securities are held of record by Vivo Opportunity Fund, L.P. ("VOF").

F4: Vivo Capital VIII, LLC ("Vivo LLC") is the general partner of VCF and VCSF. The voting members of Vivo LLC are Frank Kung, Edgar Engleman, Albert Cha, Shan Fu and Chen Yu, and none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

F5: Vivo Opportunity, LLC is the general partner of VOF. The voting members of Vivo Opportunity, LLC are Albert Cha, Gaurav Aggarwal, Shan Fu, Frank Kung and Michael Chang, none of whom has individual voting or investment power with respect to these securities. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.

F6: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.9 to $22.2, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.

F7: The price reported herein is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.4 to $21.6, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4